Advertisement

Biologic agents in the management of inflammatory eye diseases

  • Kira Michalova
  • Lyndell LimEmail author
Article

Abstract

Biologics are a new class of drugs that comprise recombinant cytokines and monoclonal antibodies directed against selected cell-surface markers. They include the tumor necrosis factor-α inhibitors infliximab, etanercept, and adalimumab; the antilymphocyte drugs rituximab and alemtuzumab; the interleukin-2 receptor blocker daclizumab; and recombinant interferon-α. This article reviews the rationale and current evidence for their use in uveitis, scleritis, and orbital inflammation.

Keywords

Etanercept Juvenile Idiopathic Arthritis Uveitis Adalimumab Alemtuzumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    International Study Group for Behcet’s Disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990, 335:1078–1080.Google Scholar
  2. 2.
    Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 2001, 358:295–296.PubMedCrossRefGoogle Scholar
  3. 3.
    Ohno S, Nakamura S, Hori S, et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362–1368.PubMedGoogle Scholar
  4. 4.
    Sfikakis PP, Kaklamanis PH, Elezoglou A, et al.: Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004, 140:404–406.PubMedGoogle Scholar
  5. 5.
    Tugal-Tutkun I, Mudun A, Urgancioglu M, et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease. Arthritis Rheum 2005, 52:2478–2484.PubMedCrossRefGoogle Scholar
  6. 6.
    Mushtaq B, Saeed T, Situnayake RD, Murray PI: Adalimumab for sight threatening uveitis in Behçet’s disease. Eye 2007, 21:824–825.PubMedCrossRefGoogle Scholar
  7. 7.
    van Laar JAM, Missoten T, van Daele PLA, et al.: Adalimumab, a new modality for Behçet’s disease? Ann Rheum 2007, 66:565–566.CrossRefGoogle Scholar
  8. 8.
    Saurenmann RK, Levin AV, Rose JB, et al.: Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology 2006, 45:982–989.PubMedCrossRefGoogle Scholar
  9. 9.
    Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244:1692–1695.PubMedCrossRefGoogle Scholar
  10. 10.
    Bodaghi B, Gendron G, Bertrand Wechsler B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91:335–339.PubMedCrossRefGoogle Scholar
  11. 11.
    Kotter I, Zierhut M, Eckstein AK, et al.: Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87:423–431.PubMedCrossRefGoogle Scholar
  12. 12.
    Lockwood CM, Hale G, Waldman H, Jayne DRW: Remission induction in Behçet’s disease following lymphocyte depletion by the anti-CD 52 antibody CAMPATH 1-H. Rheumatology 2003, 42:1539–1544.PubMedCrossRefGoogle Scholar
  13. 13.
    Buggage RR, Levy-Clarke G, Sen HN, et al.: A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflam 2007, 15:63–70.CrossRefGoogle Scholar
  14. 14.
    Nussenblatt RB, Fortin E, Schiffman R, et al.: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999, 96:7462–7466.PubMedCrossRefGoogle Scholar
  15. 15.
    Papaliodis GN, Chu D, Foster CS: Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786–789.PubMedCrossRefGoogle Scholar
  16. 16.
    Nussenblat RB, Peterson JS, Foster CS, et al.: Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 2005, 112:764–770.CrossRefGoogle Scholar
  17. 17.
    Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J: Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:185–190.PubMedGoogle Scholar
  18. 18.
    Baughman RP, Drent M, Kavuru M, et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Resp Crit Care Med 2006, 174:795–802.PubMedCrossRefGoogle Scholar
  19. 19.
    Doty JD, Mazur JE, Marc A, Judson MA: Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064–1071.PubMedCrossRefGoogle Scholar
  20. 20.
    Baughman RP, Lower EE, Bradley DA, et al.: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062–1147.PubMedCrossRefGoogle Scholar
  21. 21.
    Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN: Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006, 25:596–597.PubMedCrossRefGoogle Scholar
  22. 22.
    Gallagher M, Quinones K, Cervantes-Castaneda RE, et al.: Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007, 91:1341–1344.PubMedCrossRefGoogle Scholar
  23. 23.
    Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998, 25:1991–1994.PubMedGoogle Scholar
  24. 24.
    Carvounis PE, Herman DC, Cha S, Burke JP: Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 2006, 244:281–290.PubMedCrossRefGoogle Scholar
  25. 25.
    Reiff A, Takei S, Sadeghi S, et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411–1415.PubMedCrossRefGoogle Scholar
  26. 26.
    Smith JA, Thompson DJS, Whitcup SM, et al.: A randomized, placebo controlled, double masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Quartier P, Taupin P, Bourdeaut F, et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093–1101.PubMedCrossRefGoogle Scholar
  28. 28.
    Lovell DJ, Giannini EH, Reiff A, et al.; Pediatric Rheumatology Collaborative Study Group: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763–769.PubMedCrossRefGoogle Scholar
  29. 29.
    Tynjälä P, Lindahl P, Honkanen V, et al.: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66:548–550.PubMedCrossRefGoogle Scholar
  30. 30.
    Kahn P, Weis M, Imundo LF, Levy DM: Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006, 113:860–864.PubMedCrossRefGoogle Scholar
  31. 31.
    Biester S, Deuter C, Michels H, et al.: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91:319–324.PubMedCrossRefGoogle Scholar
  32. 32.
    Vazquez-Cobian LB, Flynn T, Lehman TJA: Adalimumab therapy for childhood uveitis. J Pediatr 2006, 149:572–575.PubMedCrossRefGoogle Scholar
  33. 33.
    Braun J, Sieper J: Biological therapies in the spondyloarthritides—the current state. Rheumatology 2004, 43:1072–1084.PubMedCrossRefGoogle Scholar
  34. 34.
    Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447–2451.PubMedCrossRefGoogle Scholar
  35. 35.
    El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002, 109:2342–2346.PubMedCrossRefGoogle Scholar
  36. 36.
    Sobrin L, Kim EC, Christen W, et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895–900.PubMedCrossRefGoogle Scholar
  37. 37.
    Van Rijthoven AW, Jacobs JW: Seronegative spondylarthropathy: variable manifestations, common characteristics. Ned Tijdschr Geneeskd 2007, 151:1377–1381.PubMedGoogle Scholar
  38. 38.
    Taban M, Dupps WJ, Mandel B, Perez V: Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006, 14:145–150.PubMedCrossRefGoogle Scholar
  39. 39.
    Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56:3248–3252.PubMedCrossRefGoogle Scholar
  40. 40.
    Suhler EB, Smith JR, Wertheim MS, et al.: A prospective trial of infliximab therapy for refractory uveitis. Arch Ophthalmol 2005, 123:903–912.PubMedCrossRefGoogle Scholar
  41. 41.
    Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89:533–536.PubMedCrossRefGoogle Scholar
  42. 42.
    Ardoin SP, Kredich D, Rabinovich E, et al.: Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up. Am J Ophthalmol 2007, 144:844–849.PubMedCrossRefGoogle Scholar
  43. 43.
    Foster CS, Tufail F, Waheed NK, et al.: Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121:437–440.PubMedCrossRefGoogle Scholar
  44. 44.
    Plskova J, Greiner K, Forrester JV: Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007, 144:55–61.PubMedCrossRefGoogle Scholar
  45. 45.
    Deuter CE, Koetter I, Guenaydin I, et al.: Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006, 26:786–791.PubMedCrossRefGoogle Scholar
  46. 46.
    Dick AD, Meyer P, James T, et al.: Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000, 84:107–109.PubMedCrossRefGoogle Scholar
  47. 47.
    Tappeiner C, Heinz C, Specker C, Heilinghaus A: Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007, 39:184–186.PubMedCrossRefGoogle Scholar
  48. 48.
    Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149–155.PubMedCrossRefGoogle Scholar
  49. 49.
    Smith JR, Levinson RD, Holland GN, et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 2001, 45:252–257.CrossRefGoogle Scholar
  50. 50.
    Hernandez-Illas M, Tozman E, Fulcher SFA, et al.: Recombinant human tumor necrosis factor receptor Fc fusion protein (etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens 2004, 30:2–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Murphy CC, Ayliffe WH, Booth A, et al.: Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111:352–356.PubMedCrossRefGoogle Scholar
  52. 52.
    Galor A, Perez VL, Hammel JP, Lowder CY: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113:2317–2323.PubMedCrossRefGoogle Scholar
  53. 53.
    Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005, 352:351–361.CrossRefGoogle Scholar
  54. 54.
    Cheung CM, Murray PI, Savage CO: Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005, 89:1542.PubMedCrossRefGoogle Scholar
  55. 55.
    Ahmadi-Simab K, Lamprecht P, Nolle B, et al.: Successful treatment of refractory anterior scleritis in primary Sjögren’s syndrome with rituximab. Ann Rheum Dis 2005, 64:1087.PubMedCrossRefGoogle Scholar
  56. 56.
    Paridaens D, van den Bosch WA, van der Loos TL, et al.: The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye 2005, 19:1286–1289.PubMedCrossRefGoogle Scholar
  57. 57.
    Durrani OM, Reuser TQ, Murray PI: Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005, 24:117–119.PubMedCrossRefGoogle Scholar
  58. 58.
    Garrity JA, Coleman AW, Matteson EL, et al.: Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004, 138:925–930.PubMedCrossRefGoogle Scholar
  59. 59.
    Adams AB, Kazim M, Lehman TJA: Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 2005, 32:374–375.Google Scholar
  60. 60.
    Salvi M, Vannucchi G, Campi I, et al.: Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007, 156:33–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Macular Research Unit, Centre for Eye Research AustraliaUniversity of MelbourneEast MelbourneAustralia

Personalised recommendations